140 related articles for article (PubMed ID: 24239174)
21. Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
Cluzeau T; Mounier N; Karsenti JM; Richez V; Legros L; Gastaud L; Garnier G; Re D; Montagne N; Gutnecht J; Gabriel Fuzibet J; Auberger P; Raynaud S; Cassuto JP
Am J Hematol; 2013 Sep; 88(9):780-3. PubMed ID: 23757315
[TBL] [Abstract][Full Text] [Related]
22. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
23. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
[TBL] [Abstract][Full Text] [Related]
24. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
25. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
26. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
27. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
[TBL] [Abstract][Full Text] [Related]
28. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.
Buckstein R; Yee K; Wells RA;
Cancer Treat Rev; 2011 Apr; 37(2):160-7. PubMed ID: 20591575
[TBL] [Abstract][Full Text] [Related]
29. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
30. Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.
Sohlberg E; Pfefferle A; Andersson S; Baumann BC; Hellström-Lindberg E; Malmberg KJ
Oncotarget; 2015 Oct; 6(33):34178-90. PubMed ID: 26497557
[TBL] [Abstract][Full Text] [Related]
31. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Cho SH; Lee WS; Joo YD
Ann Hematol; 2013 Jul; 92(7):889-97. PubMed ID: 23420388
[TBL] [Abstract][Full Text] [Related]
32. Azacitidine in the front-line treatment of therapy-related myeloid neoplasms: a multicenter case series.
Minoia C; Sgherza N; Loseto G; Greco G; Buquicchio C; Merchionne F; Toldo C; Galise I; Melpignano A; Tarantini G; Pavone V; Guarini A
Anticancer Res; 2015 Jan; 35(1):461-6. PubMed ID: 25550588
[TBL] [Abstract][Full Text] [Related]
33. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
Maslak P; Chanel S; Camacho LH; Soignet S; Pandolfi PP; Guernah I; Warrell R; Nimer S
Leukemia; 2006 Feb; 20(2):212-7. PubMed ID: 16357841
[TBL] [Abstract][Full Text] [Related]
34. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
Kim DY; Lee JH; Lee JH; Lee KH; Kim YK; Ahn JS; Kim HJ; Kim I; Yoon SS; Park S; Bae SH; Bang SM; Lee HG; Shin HJ; Lee JH; Min YH; Won JH; Mun YC; Oh D;
Ann Hematol; 2010 Jan; 89(1):15-23. PubMed ID: 19543727
[TBL] [Abstract][Full Text] [Related]
35. The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes.
van den Bosch J; Lübbert M; Verhoef G; Wijermans PW
Leuk Res; 2004 Aug; 28(8):785-90. PubMed ID: 15203276
[TBL] [Abstract][Full Text] [Related]
36. 5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients.
Diamantopoulos P; Zervakis K; Papadopoulou V; Iliakis T; Kalala F; Giannakopoulou N; Rougala N; Galanopoulos A; Bakarakos P; Variami E; Dimitrakopoulou A; Viniou NA
Anticancer Res; 2015 Sep; 35(9):5141-7. PubMed ID: 26254419
[TBL] [Abstract][Full Text] [Related]
37. [Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine].
Ueda H; Yoshida M; Kanashima H; Nakao T; Sugiyama H; Yamane T
Gan To Kagaku Ryoho; 2014 Jul; 41(7):875-7. PubMed ID: 25131875
[TBL] [Abstract][Full Text] [Related]
38. Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.
Scalzulli E; Molica M; Alunni Fegatelli D; Colafigli G; Rizzo L; Mancini M; Efficace F; Latagliata R; Foà R; Breccia M
Ann Hematol; 2019 Aug; 98(8):1919-1925. PubMed ID: 31168652
[TBL] [Abstract][Full Text] [Related]
39. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
40. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
Musto P; Maurillo L; Spagnoli A; Gozzini A; Rivellini F; Lunghi M; Villani O; Aloe-Spiriti MA; Venditti A; Santini V;
Cancer; 2010 Mar; 116(6):1485-94. PubMed ID: 20151429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
